|
|
Opko Health Inc (NASDAQ: OPK) |
|
Price: $1.6400
$0.03 
1.863%
|
| Day's High:
| $1.649999976158142
| Week Perf:
| 11.56 %
|
| Day's Low: |
$ 1.57 |
30 Day Perf: |
24.24 % |
| Volume (M): |
2,281,484 |
52 Wk High: |
$ 1.73 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$1.33 |
| Open: |
$1.59 |
52 Wk Low: |
$0.98 |
|
|
| Market Capitalization (Millions $) |
1,239 |
| Shares
Outstanding (Millions) |
755 |
| Employees |
2,275 |
| Revenues (TTM) (Millions $) |
588 |
| Net Income (TTM) (Millions $) |
-73 |
| Cash Flow (TTM) (Millions $) |
70 |
| Capital Exp. (TTM) (Millions $) |
11 |
Business Description
Opko Health Inc is a multi-billion dollar healthcare provider that specializes in diagnostic and pharmaceutical products, especially those related to genetic testing, diagnostics and medical devices along with pharmaceuticals. Founded by Dr. Phillip Frost in 1991, the company is headquartered in Miami, Florida and has a global presence across North America, Europe, Asia and South America. The company has a diverse portfolio of products and services with emphasis on precision medicine and personalized healthcare.
Opko Health has three main divisions e pharmaceuticals, diagnostics and laboratory services. They provide genomic testing and analysis to detect and treat various diseases such as cancer, hepatitis, cardiovascular diseases, endocrinology and infectious diseases. The company's diagnostics division produces a wide range of products, including genetic and infectious disease tests and imaging services. They have also developed a Point-of-Care (POC) testing device for COVID-19, which can be used at clinics, hospitals and testing centers.
The company's pharmaceutical division develops and commercializes products for various diseases such as chronic kidney disease, growth hormone deficiency, vitamin D deficiency and prostate cancer. OPKO Biologics is the subsidiary of the company which produces a range of products based on innovative technology such as RNA interference (RNAi) and gene therapy.
Opko Health also provides laboratory services to medical providers, hospitals and clinics across the world with their subsidiary BioReference Laboratories. The laboratory services include molecular diagnostics, genomic testing and pathology services. It has been recognized for quality and performance with clinical excellence awards from various medical organizations.
Opko Health has a strong pipeline of products with a focus on precision medicine and personalized healthcare. It has both in-house R&D and collaborations with other pharmaceutical companies to develop new treatment and diagnostic products that meet patient needs. The company has also received several approvals from the US Food and Drug Administration (FDA) for its products and devices.
In conclusion, Opko Health Inc is a major healthcare provider with an extensive range of products and services, and a strong focus on innovation, precision medicine and personalized healthcare. It has a global presence and is dedicated to improving patient outcomes and creating value for shareholders.
Company Address: 4400 Biscayne Blvd. Zagreb 33137 City of Zagreb
Company Phone Number: 575-4100 Stock Exchange / Ticker: NASDAQ OPK
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Mon, Mar 17 2025 12:00 PM UTC
MIAMI and JERUSALEM March 17, 2025 In a significant leap forward for biotechnology and pharmaceutical innovation, OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) have announced a pivotal collaboration to advance groundbreaking therapies in metabolic health. The alliance aims to introduce the first oral dual agonist GLP-1/glucagon peptide as a once-dail...
|
| Financing Agreement
Published Mon, Oct 7 2024 12:00 PM UTC
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program: A Strategic Move Amidst OPKO Healthns Financial ChallengesIn a significant advancement in its research and development journey, ModeX Therapeutics Inc. a subsidiary of OPKO Health, Inc. (NASDAQ: OPK), has been awarded an additional ...
|
| Shares
Published Thu, Jul 18 2024 12:00 PM UTC
OPKO Health, Inc. Announces $100 Million Share Repurchase Program
MIAMI, July 18, 2024 - OPKO Health, Inc. (NASDAQ: OPK), a leading healthcare company, has recently made an exciting announcement. The company s Board of Directors has authorized the repurchase of up to $100 million of shares of the Company s common stock. This move reflects the confidence and commitment of...
|
| Financing Agreement
Published Wed, Jul 17 2024 8:15 PM UTC
In a major financial move, OPKO Health, Inc. has announced a groundbreaking $250 million non-dilutive note purchase agreement with HealthCare Royalty, secured by OPKO s profit share payments from Pfizer for NGENLA. NGENLA, a once-weekly treatment marketed for pediatric growth hormone deficiency, has been a successful venture for OPKO Health.
This deal comes at a cru...
|
| Product Service News
Published Tue, Mar 5 2024 1:52 PM UTC
is pleased to present an article summarizing the recent findings from an AIDS Clinical Trial Group s Phase 1 study on ModeX Trispecific Antibody, a potential game-changer in the treatment and prevention of HIV. This significant study has highlighted the safety, pharmacokinetic profile, and potential benefits of using multispecific antibodies in humans. The following article...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.09 $ |
| Revenues (TTM) |
0.78 $
|
| Cash Flow (TTM) |
0.09 $ |
| Cash |
0.4 $
|
| Book Value |
1.57 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
258,416 |
| Net
Income per Employee (TTM) |
-32,040 |
| Receivable Turnover Ratio (TTM) |
6.79 |
| Inventory Turnover Ratio (TTM) |
5.42 |
| Asset Turnover Ratio (TTM) |
0.31 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.09 $
|
| Revenues (TTM) |
0.78 $ |
| Cash Flow (TTM) |
0.09 $ |
| Cash |
0.4 $
|
| Book Value |
1.57 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Service |
|
 44.13 % |
of total Revenue |
| Product |
|
23.26 % |
of total Revenue |
| Transfer of Intellectual Property and Other |
|
36.71 % |
of total Revenue |
| Rayaldee |
|
7.83 % |
of total Revenue |
| Intellectual Property and Other |
|
2.51 % |
of total Revenue |
| MEXICO |
|
4.24 % |
of total Revenue |
| US |
|
51.05 % |
of total Revenue |
| IE |
|
5.92 % |
of total Revenue |
| CL |
|
9.09 % |
of total Revenue |
| ES |
|
4.92 % |
of total Revenue |
| Pharmaceutical Transfer of Intellectual Property and Other |
|
8.54 % |
of total Revenue |
| Self-Pay Service |
|
1.43 % |
of total Revenue |
| Other Countries |
|
0.71 % |
of total Revenue |
| |
On May 3 2024 the Opko Health Inc provided following guidance
OPKO Health, Inc. (NASDAQ: OPK) has announced that they will be releasing their financial results for the first quarter of 2024 on Tuesday, May 7, 2024. The report will cover the period ending on March 31, 2024, and will be published after the close of the U.S. financial markets.
Senior management at OPKO Health will provide insights into the company's performance during a conference call and live audio webcast on May 7th at 4:30 p.m. Eastern time. Along with discussing the financial results, they will also offer a business update and provide guidance for the future.
Investors, s, and stakeholders are encouraged to tune into the conference call to gain a better understanding of OPKO Health's pe...
|
|
|
2.68% 